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Edited by Vladimir SkulachevAbstract iNOS mRNA of J774 murine macrophage cells was
cleaved by 10–23 DNAzymes. DNAzyme target site I or trans-
lation initiation site and site II have computer predicted
(MFOLD) secondary structures but site III has no secondary
structure. All the three DNAzymes cleaved the short transcripts
generated from cloned DNA almost with equal eﬃciency while
cleavage eﬃciency is higher at site III than the other two sites
on isolated iNOS mRNA. Interestingly, at intracellular level,
DNAzyme targeted at translation initiation codon (site I) having
secondary structure cleaved iNOS mRNA, and suppressed its
activity and protein expression more eﬃciently than that tar-
geted at sites II and III.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Nitric oxide, a by-product of the oxidative reaction cata-
lyzed by nitric oxide synthase (NOS) that converts L-arginine
to citrulline [1], acts as a pleiotropic mediator in various phys-
iological and pathophysiological conditions [2,3]. Nitric oxide
synthase has three major isoforms, neuronal NOS (nNOS) and
endothelial NOS (eNOS) being constitutive, inducible NOS
(iNOS) is expressed only following the induction by inﬂamma-
tory mediators such as lipopolysaccharides (LPS), interleukin-
1 (IL-1) and tumor necrosis factor-a (TNFa). Nitric oxide
produced by constitutively expressed NOSes (cNOS) is mainly
involved in cell signaling and the major purpose of iNOS seems
to be in host-defense through the cytotoxic eﬀects of high NO
levels [4]. The increased production of NO by iNOS is also
associated with various inﬂammatory diseases [5–7]. The selec-
tive inhibition of iNOS, without aﬀecting cNOS that produces
very low level of NO necessary for the signaling purposes, is of
primary importance in ameliorating inﬂammatory conditions
[8,9].
The 10–23 DNAzyme is a general purpose RNA phosphodi-
esterase, which works eﬃciently at simulated physiological
conditions [10]. It contains a 15 nucleotide conserved catalytic
domain ﬂanked by two 6–9 nucleotide substrate recognitionAbbreviation: iNOS, inducible nitric oxide synthase
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doi:10.1016/j.febslet.2006.03.004domains. The 10–23 DNAzyme cleaves RNA in presence of
divalent cation in between any purine and pyrimidine (R-Y)
junction, more eﬃciently between RU than RC [11,12]. It
can be end modiﬁed to overcome the host exonuclease activity
without reducing its eﬃciency. The modiﬁcation of its one or
two binding arm nucleotides with the locked nucleic acids
(LNA) enhances its substrate binding aﬃnity and subsequently
its catalytic activity [13,14].
Despite its cleavable junctions being ubiquitous, secondary
structure of the native RNA poses a challenge to select poten-
tial target site that can be available for DNAzyme binding.
Experimental approaches to choose best cleavable site seems
to be more reliable, as presently our ability to rationally select
target site is limited [11,15,16]. As a ﬁrst resort to gain insight
into the secondary structure of nucleic acids, generally soft-
ware based DNA/RNA folding predictions are considered.
But the actual hybridization eﬃciency in in vivo varies from
the predicted results because of unpredictable steric and topo-
logical constraints in the intracellular environment of the spe-
ciﬁc tissues. In several cases, AU junctions of initiation codon
were selected as a target site [17–19] to stop translation process
in the very beginning, presuming that it must be open at the
time of translation initiation and hence will be free for DNA-
zyme binding. With an aim to avoid laborious experiment
based target site selection and to ﬁnd out a safe target site,
we have done a comparative analysis of DNAzymes activity
targeting initiation codon and MFOLD (http://bioweb.
pasteur.fr/seqanal/interfaces/mfold-simple.html) predicted pri-
mary and secondary sites of iNOS mRNA of murine macro-
phage cells under intracellular and extracellular conditions.2. Materials and methods
2.1. Oligonucleotides
Threepairs ofPCRprimers formaking cDNAclones to generate short
iNOS mRNA fragments were SetI: 5 0-CTCCTCACGCTT-
GGGTCTTGTTC-3 0 (FP), 5 0-CCGATGTG GCCTTGTGGTGA-30
(RP); SetII: 5 0-CAGCGCTACAACATCCTGGAG-3 0 (FP), 5 0-
CCTGGGCCTCAGCTTCTCATT-3 0 (RP); SetIII : 5 0-CAGCCCA-
ACAATACAAGATGAC-30 (FP), 5 0-AGTGATGGCCGACCT-
GATG-3 0 (RP); and two DNA sequencing primers 5 0-GTCGTTAG-
AACGCGGCTAC-3 0 (FP) and 5 0-GGTTTTCACCGTCATCACC-
G-3 0 (RP) for sequencing the inserts of Pspt18 clones were synthesized
from TCGA (New Delhi, India). DNAzymes, 5 0-ggcaagccaGGC
TAGCTACAACGAgtctgagac-30 (DzI targeting site I), 5 0-ccagccaaa-
GGCTAGCTACAACGAccagtctgc-30 (DzII targeting site II), 5 0-ttgt
ttctaGGCTAGCTACAACGAttcctttgt-3 0 (DzIII targeting site III)
and their corresponding mutant DNAzymes (MDzI, MDzII and
MDzIII) were made from Sigma, UK. Mutant DNAzymes contain
TG in place of GC (underlined) in the catalytic domain of DNAzymes.blished by Elsevier B.V. All rights reserved.
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catalytic domain ﬂanked by 9 nucleotides substrate binding domains
(written in small letters) at the ends. All the DNAzymes and their
mutants have 5 0 phosphorothioate linkage and 3 0 CPG-amine C7 cap.
Primers for glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
5 0-CAGTGCCAGCCTCGTCCCGTAGA-3 0 (FP) and 5 0-CAC-
CCTGTTGCTGTAGCCGTATTC-3 0 (RP) were synthesized from
TCGA (NewDelhi, India). Randomhexamers for the ﬁrst strand cDNA
synthesis were part of the cDNA synthesis kit (Clontech, USA).2.2. Cell culture
Murine macrophage cell line J774 was obtained from International
Centre for Genetic Engineering and Biotechnology (N. Delhi, India).
Cells were propagated in RPMI-1640 medium supplemented with
2 mM glutamine, antibiotics (100 U/ml of penicillin, 100 lg/ml of
streptomycin and 0.25 lg/ml of amphotericin B), and 10% heat inacti-
vated fetal calf serum, and maintained at 37 C in a humidiﬁed incu-
bator containing 5% CO2. The culture was allowed to grow to
conﬂuence and used for further experiment. The cells were resus-
pended in RPMI-1640 at a density of 2 · 106 cells/ml. Cell viability
was determined by trypan blue exclusion. Lipopolysaccharide (LPS)
from E. coli (strain 055:B8, Sigma) was used to induce iNOS in murine
macrophage cells.2.3. Isolation of mRNA
Total RNA from LPS induced and uninduced cells were isolated
using EZ-RNA isolation kit (Biological Industries, Israel). Poly
A + RNA was isolated from total RNA using oligotex mRNA midi
kit (Qiagen) and quantitated by spectrophotometry (Perkin–Elmer
Lambda 35 UV/VIS spectrophotometer).2.4. In vitro transcription and DNAzyme cleavage assays in cell free
system
Three Pspt18 clones having the insert sizes 400, 368 and 610 bp were
made by RT-PCR of iNOS mRNA using the primer sets I, II and III,
respectively. The inserts in Pspt18 clones were sequenced by an auto-
mated capillary DNA sequencer, ABI 3370, Prism (Applied Biosys-
tems, Foster City, CA). The [a-32P]UTP labeled transcripts of sizes
400 nts (SI, contains DzI site), 368 nts (SII, contains DzII site) and
610 nts (SIII, contains DzIII site) were generated by using SP6 RNA
polymerase (Roche Applied Science) from their corresponding linear-
ized Pspt18 clones.
Cell free DNAzyme cleavage assays of the in vitro transcripts and
poly A+ iNOS RNA from LPS induced or uninduced macrophage cells
were carried out in a 20 ll reaction volume containing substrate RNA,
DNAzyme, 5 mM Tris–HCl, pH 7.5, 10 mM MgCl2, and 150 mM
NaCl at 37 C for 2 h [18]. In the case of in vitro transcripts, reaction
was stopped by transferring aliquots of the reaction mixture into form-
amide loading buﬀer (90% formamide and 20 mM EDTA). The
cleaved and uncleaved RNAs were then separated by gel electrophore-
sis in a 5% urea denaturing polyacrylamide gel and autoradiographed.
In the case of polyA+ RNA substrate cleavage activities were ascer-
tained by RT-PCR as described below.2.5. DNAzyme cleavage assays in transfected cells
Semi conﬂuent (60–80%) macrophage cells were transfected with
DNAzymes and their mutants using lipofectamine reagent (GIBCO
BRL) following the supplier’s protocol in a 24 well plate. Initially
5 · 105 cells were seeded in each well and incubated for 24 h at 37 C
in complete medium. Transfections were carried out in Opti-MEM I
reduced serum medium (GIBCO BRL) for 5 h followed by LPS
(1 lg/ml) challenge for 4 h in serum containing medium. Total RNA
from the cells from each experiment was isolated and quantitated.
DNAzyme activities on isolated mRNA and in DNAzyme transfec-
ted cells were assessed by semi quantitative RT-PCR using the primer
sets I, II and III for DNAzymes (Dz and MDz) I, II and III, respec-
tively. RT-PCR products were separated in 1.5% agarose gel. The dif-
ferences in integrated density values (IDV) of RT-PCR products
obtained with or without DNAzyme treatment (Alpha DigiDoc
1201, USA) were used as a measure of cleavage activity. GAPDH
(993 bp) was kept as a house keeping gene for all the RT-PCR
reactions.2.6. Griess nitrite assay and Western blot analysis
Griess nitrite assays for the cell-free supernatants and Western blot
analysis of the cell extracts were carried out after 16 h of LPS induction
in DNAzyme transfected and untransfected cells. By Griess reaction,
the NO level was measured as its stable oxidative product nitrites as
described earlier [20]. Brieﬂy, 100 ll of cell free supernatant was incu-
bated for 10 min at room temperature with an equal volume of Griess
reagent (0.1% naphthalene diamine dihydrochloride, 1% sulfanilamide
in 5% phosphoric acid) and absorbance was measured at 546 nm using
sodium nitrite as standard.
For Western blot analysis cell extracts were prepared by the method
of Korhonen et al. [21]. Cell pellets were lysed in ice-cold extraction
buﬀer (10 mM Tris base, 5 mM EDTA, 50 mM NaCl, 1% Triton X-
100, 0.5 mM phenylmethyl sulfonyl ﬂuoride, 2 mM Na-orthovanadate,
10 lg/ml leupeptin, 25 lg/ml aprotinin, 1.25 mM NaF, 1 mM Na-
pyrophosphate, 10 mM N-octyl-b-D-glucopyranoside) and incubated
on ice for 15 min for extraction and then centrifuged. Supernatants
were boiled for 5 min in the sample buﬀer containing 62.5 mM Tris–
HCl, pH 6.7, 20% glycerol, 2% SDS, and 10 mM 2-mercaptoethanol.
Protein estimation of the supernatants was done by Bradford Coomas-
sie brilliant blue method (Bio-Rad, Richmond, CA) using bovine ser-
um albumin as standard. Cell extracts were fractionated by sodium
dodecyl sulphate–polyacrylamide gel electrophoresis [22] by loading
10 lg of protein in each lane and blotted onto a nitrocellulose mem-
brane. The blot was probed with 1:1000 diluted mouse monoclonal
anti-iNOS antibody (Sigma, UK) and developed with secondary anti-
body (peroxidase conjugated goat anti-mouse IgG, Sigma, UK) as de-
scribed by Sambrook et al. [23]. The housekeeping gene GAPDH was
probed with the mouse monoclonal anti GAPDH antibody (Santa
Cruz Biotechnology, CA).3. Results
3.1. Secondary structure determination of iNOS mRNA
MFOLD generated partial secondary structure of 3991 nts
iNOS mRNA of Mus musculus (NCBI Accession No.
NM_010927) around selected DNAzyme target sites I, II and
III are shown in the Fig. 1. Intramolecular hydrogen bonding
or secondary structure formations are seen in the DNAzyme
binding sites of site I and II but no such structures are ob-
served at siteIII.3.2. Cleavage of short in vitro transcripts
In vitro transcripts of sizes 400 nts (SI), 368 nts (SII) and 610
nts (SIII) contained the DNAzyme target sites I, II and III,
respectively. Generation of RNA fragments of 300 and
100 nts by DzI, 225 and 143 nts by DzII, and 392 nts and
218 nts by DzIII indicated speciﬁcity of the designed DNA-
zymes (Fig. 2). Appreciable RNA cleavage activity of none
of the mutant DNAzymes was observed at any one of the tar-
get sites. Cleavage activities of all the three DNAzymes in-
creased with their increasing concentrations.3.3. In vitro cleavage of iNOS mRNA
The cleavage activities of the three DNAzymes on three tar-
get sites in iNOS mRNA substrate (Fig. 3) diﬀer from that on
its short fragments (Fig. 2), however, in both the cases higher
activities were realized with their increasing concentrations,
and less than 10% activities were observed with their mutant
DNAzymes.
3.4. Intracellular RNA cleavage activity
The increased RNA cleavage activities of all the three de-
signed DNAzymes were also observed when macrophage cells
were transfected with increasing concentration of DNAzymes.
Fig. 1. MFOLD predicted secondary structure of 3991 nts long iNOS mRNA around the three DNAzyme target sites, I (185–186 nt), II (1550–
1551 nt) and III (683–684 nt).
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among the three DNAzymes when IDV values of the bands
were compared (Fig. 4). With 1 lg of DNAzyme, 80% cleavage
was observed at siteI, and 30% and 48% at sites II and III,
respectively, while with 3 lg of DNAzyme, 87%, 53% and
57% cleavage were observed at sites I, II and III, respectively.
The highest mRNA cleavage activities were observed with 5 lg
of DNAzymes but no signiﬁcant cleavage occurred at this con-
centration when transfected with their mutants.
3.5. Reduction of nitrite level as measured by Griess assay
Griess nitrite assays of DNAzyme transfected cell superna-
tants also indicated the reduction of iNOS activities by DNA-Fig. 2. In vitro cleavage analysis of [a32P]-UTP labeled short transcripts S
respectively, and their corresponding mutants (MDz) in 5% urea-polyacrylazymes. Results in the Fig. 5, demonstrate the signiﬁcant
decrease of nitrite formation with all the three DNAzymes.
Maximum inhibition of nitrite production was observed with
5 lg of DNAzymes. Inhibition of nitrite production was max-
imum with DzI followed by DzIII and DzII. Mutant DNA-
zymes did not show signiﬁcant inhibition of nitrite formation
(Fig. 5).
3.6. Inhibition of iNOS expression
Estimation of iNOS expression by Western blot analysis
with monoclonal antibody also indicated the inhibition of
iNOS expression in the DNAzyme transfected cells (Fig. 6).
Like increased RNA cleavage and inhibition of NO produc-I (400 nt), SII (368 nt) and SIII (610 nt) by DNAzymes I, II and III,
mide gel. P1 and P2 indicate the DNAzyme cleaved products.
Fig. 3. In vitro cleavage analysis of the DNAzyme treated iNOS mRNA extracted from LPS induced macrophage cells as measured by RT-PCR
using GAPDH as the house-keeping gene. A representative results of the three independent sets of experiments are shown in (A), and the percentage
cleavage of mRNA at each target site was calculated by IDV of the bands in comparison to their respective controls (B). P values of the percentage
cleavage plotted in B were 60.005.
Fig. 4. Intracellular cleavage of LPS induced iNOS mRNA in macrophage cells by DNAzymes on transfection with lipofectamine as described under
Section 2. One set of results of the three independent sets of experiments are shown in (A). Control experiments were done with mock transfected
cells. The percentage cleavage at each target site was calculated by IDV of the bands in (A) in comparison to their respective controls. P values of the
percentage cleavage plotted in B were 60.005.
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Fig. 5. Inhibition of nitric oxide production measured as nitrite concentration, in the culture supernatants of DNAzyme treated LPS challenged
murine macrophages. P values of the nitrite concentration plotted above with three independent sets of experiments were 60.005.
Fig. 6. Western blot analysis of iNOS protein expression in LPS induced DNAzyme transfected murine macrophage cells as described under Section
2 (A). A set of results of the three independent sets of experiments are shown in (A). The control experiments were done with mock transfected cells.
The percentage inhibition of protein expression at each target site was calculated by IDVs of the blots in comparison to their respective controls. P
values of the percentage inhibition plotted in (B) were 60.005.
2050 I. Chaudhury et al. / FEBS Letters 580 (2006) 2046–2052tion in DNAzyme transfected cells, iNOS expressions were
also found to be reduced signiﬁcantly with the increasing con-
centration of DNAzymes. The maximum inhibition of expres-sion was observed with DzI followed by DzIII and DzII.
Mutant DNAzymes had no signiﬁcant eﬀect on iNOS expres-
sion (Fig. 6).
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Our results indicate that suppression of iNOS activity in mur-
ine macrophage cells is mediated through the cleavage of its
mRNA at speciﬁc sites by the three designed DNAzymes. Ex-
pected sizes of designed DNAzymes I, II and III cleaved iNOS
mRNA fragments indicated their speciﬁcities. The decrease of
substrate RNA and the increase of cleaved RNA products with
the increasing concentration of DNAzymes suggest the DNA-
zyme dependent cleavage of iNOSmRNA. Similar observations
were also made in the in vitro experiment with isolated iNOS
mRNA substrate and in DNAzyme transfected cells (Figs. 3
and 4). Diﬀerential activities (Figs. 3 and 4) of three DNAzymes
at their respective sites are likely due to their diﬀerential binding
or hybridization eﬃciencies at the target sites. The diﬀerences in
cleavage activities of DzI and DzIII in in vitro experiments
(Fig. 3), and in transfected cells (Fig. 4) suggest the variation
of secondary or higher order structure of isolated and intracellu-
lar iNOS mRNAs. Again intracellular diﬀerential cleavage
activities of the DNAzymes are also reﬂected in NO production
and iNOS protein expression (Figs. 5 and 6). The mutant DNA-
zymes did not show appreciable cleavage activity when treated
with short in vitro transcribed RNA substrates (Fig. 2), how-
ever, indirect measurements through RT-PCR showed less than
10% cleavage activity (Figs. 3 and 4).
Higher cleavage activity of DzIII than DzI and DzII in cell
free system is as expected from MFOLD predicted substrate
RNA structure. MFOLD prediction was also found to corre-
late with the observed results when activity of DzIII in intra-
cellular level was found to be better than that of DzII.
However, signiﬁcantly higher intracellular eﬃciency of DzI
than other two DNAzymes contradicts software prediction
and draws special attention at structural variations of mRNA
region around translation initiation codon in the cellular envi-
ronment. Probable explanation of this variation may be the
need of keeping translation start site free of any secondary
structure for initiation of translation. This ﬁnding thus sug-
gests that, initiation codon can be used as a safe and better tar-
get than other computer predicted primary sites for DNAzyme
mediated inhibition of iNOS expression. However, this should
be veriﬁed further in in vivo animal experiments.
The lack of any highly speciﬁc pharmacological substrate
based iNOS inhibitor demands search for a strong inhibitor
that can eﬃciently discriminate between all the three isoforms
of NOS [2,9,24]. Antisense suppression of iNOS mRNA is re-
ported claiming better speciﬁcity and silencing compared with
non nucleic acid based inhibition [9,25]. In view of the site-spe-
ciﬁc cleavage activity without the aid of any protein, and better
intracellular stability than ribozyme, 10–23 DNAzyme has got
some advantages over other nucleic acid based gene silencing.
Highly eﬃcient inhibition of iNOS gene expression by DNA-
zyme as observed in this study strongly suggests its usefulness
as a selective iNOS inhibitor. However, further studies using
DNAzyme or LNAzyme in animal model are necessary for
further evaluation of these DNAzymes as potential therapeu-
tics to iNOS induced inﬂammatory diseases.Acknowledgements: The authors express their gratitude to Prof. S.K.
Brahmachari, Director, Institute of Genomics and Integrative Biology,
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